Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders

Donglin Liu(Boston University), Xudong Zhang(Anhui Medical University), Qingjiang Chen(First Affiliated Hospital of Zhengzhou University), Jieming Zhang(Lymphoma Research Foundation), Mingzhi Zhang(Soochow University), Meng Dong(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Yanjie Wang(Zhengzhou University), Siyu Qian(First Affiliated Hospital of Zhengzhou University), Mengjie Ding(First Affiliated Hospital of Zhengzhou University), Shanshan Ma(First Affiliated Hospital of Zhengzhou University)
Research Square
May 22, 2023
10.21203/rs.3.rs-2921149/v1
Cited by 0

Related Papers

Estimation of Winter Wheat Above-Ground Biomass Using Unmanned Aerial Vehicle-Based Snapshot Hyperspectral Sensor and Crop Height Improved Models
|Remote Sensing|2017|358
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
|Bioconjugate Chemistry|2015|302
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
|The Lancet Respiratory Medicine|2022|145
miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42
|Digestive Diseases and Sciences|2011|140